New clinical trial to examine medication to treat social withdrawal in Fragile X and autism

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

Rush is the only site in Illinois and one of 21 hospitals in the U.S. participating in the trial for Fragile X.

Fragile X syndrome is a characterized by impaired social function, cognition and speech, as well as attention deficits and anxiety.

People with Fragile X, autism or often display social impairment including social withdrawal and anxiety and have difficulty communicating and interacting with others. Although there are behavioral and , there are no approved medications for the treatment of social or communication difficulties in Fragile X, autism and autism spectrum disorders.

"The condition can be severely debilitating and this medication has the potential to play a much needed role in improving the core symptoms of fragile X syndrome and helping patients and their families achieve an improved quality of life," said Dr. Elizabeth Berry-Kravis, pediatric neurologist at Rush and principal investigator of the study.

The study is sponsored by Seaside Therapeutics, Inc, and will test the efficacy, safety and tolerability of the drug called STX209 (arbaclofen).

Racemic baclofen (mixture of arbaclofen and esbaclofen) is approved by the FDA to treat spasticity and stiff muscles due to cerebral palsy or other forms of brain or spinal cord injury, but arbaclofen, the more active form of baclofen, is not FDA approved.

"There is some evidence that the medication may help with social behaviors in people with developmental disabilities," said Berry-Kravis, who is a professor of pediatrics, neurology and biochemistry at Rush University.

Participants in the randomized, double-blind, placebo controlled phase III trial will be randomized to receive either the study drug, STX209, or a placebo. The clinical trial will include screening, treatment, withdrawal of medication, and a follow-up period. Subjects who complete the study may be eligible to enroll in a subsequent open-label study in which all subjects are treated with STX209.

STX209 has been studied in a previous small placebo-controlled trial in children and adults with and showed evidence of benefit for .

"Previous research has found that from one-quarter to one-half of people with fragile X have autism spectrum disorders," said Berry-Kravis.

"This trial is exciting, because it represents the culmination of 20 years work in fragile X research since discovery of the fragile X gene in 1991," said Kravis. "We're not expecting this to cure fragile X or autism, but it's a very important step in the development of new treatments."

add to favorites email to friend print save as pdf

Related Stories

Secret funding fosters hope for new drugs for autism

Sep 15, 2010

Funding from an anonymous wealthy family has been the secret to progress, at long last, in developing drugs that show promise for helping millions of people worldwide with Fragile X syndrome, the most common genetic cause ...

Measuring intellectual disability

Jun 24, 2009

Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. ...

Recommended for you

Hong Kong makes Ebola 'contingency' measures

1 hour ago

Hong Kong said Wednesday it was quarantining all people from Guinea, Sierra Leone and Liberia who were showing Ebola-like symptoms on arrival in the city, as fears grow worldwide about the spread of the deadly virus.

EU ready for Ebola threat: sources

4 hours ago

The European Union is equipped and ready to treat victims should the deadly Ebola virus, which has killed hundreds in West Africa, be found in member states, EU sources said Wednesday.

Reducing kidney injury using a quality improvement method

9 hours ago

Using quality improvement measures in eight of the 10 hospitals in the Northern New England Cardiovascular Disease Study Group, researchers have found a way to reduce kidney injury in patients undergoing a procedure with ...

App for headache sufferers shows success

21 hours ago

A unique app that helps headache sufferers to record the severity and regularity of their pain is being used as part of a Griffith research study.

User comments